AI Summary
This article discusses the discovery of selective Proteolysis-Targeting Chimera (PROTAC) degraders targeting the protein tyrosine phosphatase 1B (PTP1B) as potential long-term hypoglycemic agents. These agents could have implications for the treatment of conditions such as diabetes by targeting specific proteins involved in glucose metabolism.